Chimeric plasminogen activators.

摘要

Chimeric plasminogen activators comprising at least the enzymatic region of urokinase-type plasminogen activator in combination with polypeptide material from another source, will sometimes show improved thrombolytic potency in vivo. The other polypeptide material is preferably a fragment, without substantial fibrin-affinity from the non-enzymatic portion of tissue-type plasminogen activator. The most preferred product is a chimeric molecule comprising aminoacids 1 to 3 and 87 to 274 of tissue-type plasminogen activator fused to aminoacids 138 to 411 of urokinase-type plasminogen activator. These products may occur in single-chain or two-chain form and may be used in pharmaceutical compositions for the treatment of thromboembolic diseases. <IMAGE>